This study is to evaluation the efficacy and safety of Zotarolimus-Eluting Stent in patients with long coronary artery disease of 25 mm or longer.
Study objectives: From this observational prospective study, the efficacy and safety of Zotarolimus-Eluting Stent in patients with coronary artery disease longer than 25mm is planned to be investigated. Background: Long coronary artery lesions are observed in 20% of all coronary interventions, and are associated with poor clinical outcomes. Zotarolimus-Eluting Stents are a new type of stent that combines the advantages of an Endeavour Resolute stent (drug eluting stent) and Integrity stent (bare metal stent). In other words, BioLinx polymer is used which is an advantage of Endeavour Resolute stent to secure clinical efficiency through stable drug release while ensuring flexibility and excellent deliverability, which is the advantage of Integrity stent. To date, there are only few studies to evaluate the efficacy and safety of Zotarolimus-Eluting Stent in the treatment of coronary artery disease. Therefore, the investigators planned to carry out a multicenter, prospective observational study to evaluated the efficacy and safety of Zotarolimus-Eluting Stent in patients with long coronary artery disease of 25 mm or longer.
Study Type
OBSERVATIONAL
Enrollment
2,000
Percutaneous coronary intervention using zotarolimus-eluting stent
Gyeongsang National University Changwon Hospital
Changwon, South Korea
Dankook University Hospital
Cheonan, South Korea
Target lesion failure
Composite endpoint of clinically driven target lesion revascularization, myocardial infarction or cardiac death related to target vessel
Time frame: Index admission to 12 months
All-cause death
Cumulative incidence rate of all-cause death at each visit
Time frame: Index admission, 1 month, 6 months, 12 months
Cardiac death
Cumulative incidence rate of cardiac death at each visit
Time frame: Index admission, 1 month, 6 months, 12 months
Myocardial Infarction
Cumulative incidence rate of myocardial infarction at each visit
Time frame: Index admission, 1 month, 6 months, 12 months
All-cause death or Myocardial infarction
Cumulative incidence rate of all-cause death or myocardial infarction at each visit
Time frame: Index admission, 1 month, 6 months, 12 months
Cardiac death or Myocardial infarction
umulative incidence rate of cardiac death or myocardial infarction at each visit
Time frame: Index admission, 1 month, 6 months, 12 months
Target vessel revascularization
Cumulative incidence rate of target vessel revascularization at each visit
Time frame: Index admission, 1 month, 6 months, 12 months
Target lesion revascularization
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Konkuk University Medical Center
Chungju, South Korea
Daegu Catholic University Hospital
Daegu, South Korea
Keimyung University Dongsan Medical Center
Daegu, South Korea
Kyungpook National University Hospital
Daegu, South Korea
Yeungnam University Medical Center
Daegu, South Korea
Eulji Medical Center
Daejeon, South Korea
Kongyang Univeristy Hospital
Daejeon, South Korea
Chonnam National University Hospital
Gwangju, South Korea
...and 10 more locations
Cumulative incidence rate of target lesion revascularization at each visit
Time frame: Index admission, 1 month, 6 months, 12 months
Stent thrombosis
Cumulative incidence rate of stent thrombosis at each visit
Time frame: Index admission, 1 month, 6 months, 12 months